BEIJING, Dec. 6, 2010 /PRNewswire-Asia-FirstCall/ -- China
Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a
leading China-based advanced
in-vitro diagnostic ("IVD") company, today announced that its
wholly-owned subsidiaries, Beijing GP Medical Technologies Co.,
Ltd. ("GP Medical") and Beijing Yuande Bio-Medical Engineering Co.,
Ltd. ("Beijing Yuande"), have been ranked 12th and 415th,
respectively, in the Deloitte Technology Fast 500 Asia Pacific 2010
program. GP Medical operates the fast growing molecular diagnostic
business of the Company, and Beijing Yuande operates the
immunodiagnostic business of the Company.
"We are honored to be named in the Deloitte Technology Fast 500
Asia Pacific for 2010," commented Mr. Xiaodong Wu, Chairman and Chief Executive
Officer of the Company. "We believe that there is good market
potential in both molecular diagnostics and immunodiagnostics in
China, and we will continue to
focus on capturing these market opportunities."
About China Medical Technologies, Inc.
China Medical Technologies, Inc. is a leading China-based advanced IVD company using
molecular diagnostic technologies including Fluorescent in situ
Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an
immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay
(ECLIA), to develop, manufacture and distribute diagnostic products
used for the detection of various cancers, diseases and disorders
as well as companion diagnostic tests for targeted cancer drugs.
The Company generates all of its revenues in China through the sale of diagnostic
consumables including FISH probes, SPR-based DNA chips and ECLIA
reagent kits to hospitals which are recurring users of the
consumables for their patients. The Company sells FISH probes and
SPR chips to large hospitals through its direct sales force and
ECLIA reagent kits to small and mid-size hospitals through
distributors. For more information, please visit
http://www.chinameditech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements constitute "forward-looking" statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar
statements. Such statements involve certain risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. Further information regarding these
and other risks is included in the Company's filings with the U.S.
Securities and Exchange Commission, including its annual report on
Form 20-F. The Company does not undertake any obligation to update
any forward-looking statement as a result of new information,
future events or otherwise, except as required under applicable
law.
Contact
|
|
|
|
Winnie Yam
|
|
Tel: 852-2511-9808
|
|
Email: IR@chinameditech.com
|
|
|
SOURCE China Medical Technologies, Inc.